By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics and Celera today announced they have signed a definitive agreement for the purchase of Celera by Quest for $671 million, or $344 million net of cash and short-term investments.

Quest will pay $8 for each share of Celera. The deal includes $327 million in acquired cash and short-term investments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Nature has retracted a 2002 epigenetics paper for image manipulation.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.